NCT03947255

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Seagen Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stopping treatment.

Detailed description

This is a study to determine the safety and efficacy of brentuximab vedotin in subjects with classic Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T cell lymphoma (PTCL) who experienced complete response (CR) or partial response (PR) with a brentuximab vedotin-containing regimen and subsequently experienced disease progression or relapse.

Conditions

• Hodgkin Lymphoma
• Peripheral T Cell Lymphoma
• Anaplastic Large Cell Lymphoma

Interventions

Type	Name	Description
DRUG	brentuximab vedotin	1.8 mg/kg given intravenously (IV)

Timeline

• Start date: 2019-10-28
• Primary completion: 2022-11-06
• Completion: 2022-11-06
• First posted: 2019-05-13
• Last updated: 2023-10-13
• Results posted: 2023-10-13

Locations

19 sites across 1 country: United States

Regulatory

• FDA-regulated drug study